# US 2026/0076969 A1 · Methods and compositions for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076969 A1
- Document ID: US20260076969A1
- Status: Published application
- Kind: A1
- Application number: 19/323,888
- Filed: 2025-09-09
- Published: 2026-03-19
- Earliest claimed: 2024-09-13
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, The University of Texas System
- Inventors: Yonathan Lissanu; Nicholas Blazanin
- Web page: https://patentgrep.com/patent/US20260076969A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides compositions and methods for the treatment of cancer. The present disclosure further provides therapeutic and pharmaceutical compositions comprising a ROCK inhibitor and an OXPHOS inhibitor. Aspects of the disclosure further relate to methods for treating diseases or disorders associated with a mutation in a subunit of a SWI/SNF chromatin remodeling complex.

## Claims

### Claim 1

A method of treating a subject afflicted with or at risk of developing a cancer comprising a mutation in a subunit of a SWI/SNF chromatin remodeling complex, the method comprising administering to the subject an effective amount of a ROCK inhibitor and an effective amount of an OXPHOS inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ROCK inhibitor is selected from the group consisting of belumosudil (KD025), AT-13148, BA-210, β-elemene, chroman 1, DJ4, fasudil, GSK-576371, GSK429286A, H-1152, hydroxyfasudil, ibuprofen, LX-7101, netarsudil, RKI-1447, ripasudil, TCS-7001, thiazovivin, verosudil, Y-27632, Y-30141, Y-33075, and Y-39983.

### Claim 3 (depends on 1)

The method of claim 1, wherein the OXPHOS inhibitor is selected from the group consisting of IACS-010759 (IACS-10759), metformin, phenformin, HP661, IM156 (lixumistat, HL156A), BAY 87-2243, VLX600, lonidamine, atovaquone, AG311, Mito-Met10 (norMitoMet), mubritinib, carboxyamidotriazole (CAI), ME344, fenofibrate, deguelin, papaverine, α-TOS, neoantimycin F, ADDA 5, Gboxin, S-Gboxin, oligomycin A, apoptolidin, bedaquiline, DX3-213B, BAY-179, 4-methyl-2-oxovaleric acid (ketoleucine, 4-MOV, KIC), diphenylamine hydrochloride, and carbonylcyanide 3-chlorophenylhydrazone (CCCP), carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), 3-nitropropionic acid, amobarbital, antimycin A, arsenic trioxide, atpenin A5, aurovertin B, BAM 15, Bz-423, berberine, canagliflozin, calcimycin (A-23187), cyanine5 alkyne (alkyne-Cy5), DX2-201, DX3-234, DX3-235, hydrocortisone, IM176OUT05, malonate, mIBG, Mito-LND (Mito-Lonidamine), Mito-Q, MPTP (1-methyl 4-phenyl 1,2,3,6 tetrahydropyridine), myxothiazol nitric oxide, nefazodone, nonactin, parimifasor (LYC-30937), piericidin A, pioglitazone, pyrvinium, ranolazine, rosiglitazone, rotenone, RTB70, TRC1, OXPHOS-IN-1, SMV-32, stigmatellin, TRAP1-IN-2, TRAP1-IN-1, SCAL-255, SCAL-266, siccanin, tetrathiomolybdate, tiabendazole, and TTFA (thenoyltrifluoroacetone).

### Claim 4 (depends on 1)

The method of claim 1, wherein the ROCK1 inhibitor is belumosudil (KD025) and the OXPHOS inhibitor is IACS-010759 (IACS-10759), metformin, phenformin, or IM156.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subunit of the SWI/SNF chromatin remodeling complex is ARID1A or SMARCA4.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cancer is resistant to chemotherapy, immunotherapy, or an inhibitor of KRAS.

### Claim 7 (depends on 1)

The method of claim 1, wherein the effective amount of the ROCK1 inhibitor is about 1 mg/kg to about 2500 mg/kg body weight, about 10 mg/kg to about 2000 mg/kg body weight, about 50 mg/kg to about 1750 mg/kg body weight, about 100 mg/kg to about 1500 mg/kg body weight, about 200 mg/kg to about 1200 mg/kg body weight, about 100 mg/kg to about 800 mg/kg body weight, about 100 mg/kg to about 600 mg/kg body weight, about 200 mg/kg boy weight to about 500 mg/kg body weight, or about 200 mg/kg to about 400 mg/kg body weight.

### Claim 8 (depends on 7)

The method of claim 7, wherein the effective amount of the ROCK1 inhibitor is about 1 mg/kg to about 2500 mg/kg body weight per day, about 10 mg/kg to about 2000 mg/kg body weight per day, about 50 mg/kg to about 1750 mg/kg body weight per day, about 100 mg/kg to about 1500 mg/kg body weight per day, about 200 mg/kg to about 1200 mg/kg body weight per day, about 100 mg/kg to about 800 mg/kg body weight per day, about 100 mg/kg to about 600 mg/kg body weight per day, about 200 mg/kg boy weight to about 500 mg/kg body weight per day, or about 200 mg/kg to about 400 mg/kg body weight per day.

### Claim 9 (depends on 1)

The method of claim 1, wherein the effective amount of the OXPHOS inhibitor is about 0.5 mg/kg to about 2500 mg/kg body weight, about 10 mg/kg to about 2000 mg/kg body weight, about 50 mg/kg to about 1750 mg/kg body weight, about 200 mg/kg to about 1000 mg/kg body weight, about 200 mg/kg to about 800 mg/kg body weight, about 400 mg/kg to about 600 mg/kg body weight, about 0.5 mg/kg to about 20 mg/kg body weight, about 0.5 mg/kg to about 15 mg/kg body weight, about 0.5 mg/kg to about 10 mg/kg body weight, about 0.5 mg/kg to about 9 mg/kg body weight, about 0.5 mg/kg to about 8 mg/kg body weight, about 0.5 mg/kg to about 7 mg/kg body weight, about 0.5 mg/kg to about 6 mg/kg body weight, about 0.5 mg/kg to about 5 mg/kg body weight, about 0.5 mg/kg to about 4 mg/kg body weight, about 0.5 mg/kg to about 3 mg/kg body weight, about 0.5 mg/kg to about 2 mg/kg body weight, or about 0.5 mg/kg to about 1.5 mg/kg body weight.

### Claim 10 (depends on 9)

The method of claim 9, wherein the effective amount of the OXPHOS inhibitor is about 0.5 mg/kg to about 2500 mg/kg body weight per day, about 10 mg/kg to about 2000 mg/kg body weight per day, about 50 mg/kg to about 1750 mg/kg body weight per day, about 200 mg/kg to about 1000 mg/kg body weight per day, about 200 mg/kg to about 800 mg/kg body weight per day, about 400 mg/kg to about 600 mg/kg body weight per day, about 0.5 mg/kg to about 20 mg/kg body weight per day, about 0.5 mg/kg to about 15 mg/kg body weight per day, about 0.5 mg/kg to about 10 mg/kg body weight per day, about 0.5 mg/kg to about 9 mg/kg body weight per day, about 0.5 mg/kg to about 8 mg/kg body weight per day, about 0.5 mg/kg to about 7 mg/kg body weight per day, about 0.5 mg/kg to about 6 mg/kg body weight per day, about 0.5 mg/kg to about 5 mg/kg body weight per day, about 0.5 mg/kg to about 4 mg/kg body weight per day, about 0.5 mg/kg to about 3 mg/kg body weight per day, about 0.5 mg/kg to about 2 mg/kg body weight per day, or about 0.5 mg/kg to about 1.5 mg/kg body weight per day.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of lung cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), brain cancer, glioblastoma, medulloblastoma, skin cancer, melanoma, pancreatic cancer, colorectal cancer, appendiceal cancer, hematopoietic cancer, B-cell lymphoma, leukemia, myeloma, breast cancer, head and neck cancer, prostate cancer, kidney cancer, bladder cancer, liver cancer, esophageal cancer, stomach cancer, thyroid cancer, small bowel adenocarcinoma, hepatobiliary cancer, gynecological cancer, cervical cancer, uterine cancer, and ovarian cancer.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is a mammalian subject.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject is a human subject.

### Claim 14 (depends on 1)

The method of claim 1, wherein said administering comprises oral administration, buccal administration, injection, microneedle administration, vaginal administration, inhalation, intraosseous administration, transnasal application, topical administration, transdermal application, or rectal administration.

### Claim 15 (depends on 1)

The method of claim 1, further comprising administering a second therapy to said subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein said second therapy is selected from the group consisting of chemotherapy, radiation therapy, immunotherapy, and surgery.

### Claim 17 (depends on 1)

The method of claim 1, further comprising administering a pharmaceutical composition comprising the effective amount of the ROCK inhibitor or the effective amount of the OXPHOS inhibitor to said subject.

### Claim 18 (depends on 1)

The method of claim 1, further comprising administering a first pharmaceutical composition comprising the effective amount of the ROCK inhibitor and a second pharmaceutical composition comprising the effective amount of the OXPHOS inhibitor to said subject.

### Claim 19 (depends on 17)

The method of claim 17, wherein the pharmaceutical composition comprises the effective amount of the ROCK inhibitor and the effective amount of the OXPHOS inhibitor.

### Claim 20

A pharmaceutical composition comprising an effective amount of a ROCK inhibitor and an effective amount of an OXPHOS inhibitor.

### Claim 21 (depends on 20)

The pharmaceutical composition of claim 20, wherein the ROCK inhibitor is selected from the group consisting of belumosudil (KD025), AT-13148, BA-210, β-elemene, chroman 1, DJ4, fasudil, GSK-576371, GSK429286A, H-1152, hydroxyfasudil, ibuprofen, LX-7101, netarsudil, RKI-1447, ripasudil, TCS-7001, thiazovivin, verosudil, Y-27632, Y-30141, Y-33075, and Y-39983.

### Claim 22 (depends on 20)

The pharmaceutical composition of claim 20, wherein the OXPHOS inhibitor is selected from the group consisting of IACS-010759 (IACS-10759), metformin, phenformin, HP661, IM156 (lixumistat, HL156A), BAY 87-2243, VLX600, lonidamine, atovaquone, AG311, Mito-Met10 (norMitoMet), mubritinib, carboxyamidotriazole (CAI), ME344, fenofibrate, deguelin, papaverine, α-TOS, neoantimycin F, ADDA 5, Gboxin, S-Gboxin, oligomycin A, apoptolidin, bedaquiline, DX3-213B, BAY-179, 4-methyl-2-oxovaleric acid (ketoleucine, 4-MOV, KIC), diphenylamine hydrochloride, and carbonylcyanide 3-chlorophenylhydrazone (CCCP), carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), 3-nitropropionic acid, amobarbital, antimycin A, arsenic trioxide, atpenin A5, aurovertin B, BAM 15, Bz-423, berberine, canagliflozin, calcimycin (A-23187), cyanine5 alkyne (alkyne-Cy5), DX2-201, DX3-234, DX3-235, hydrocortisone, IM176OUT05, malonate, mIBG, Mito-LND (Mito-Lonidamine), Mito-Q, MPTP (1-methyl 4-phenyl 1,2,3,6 tetrahydropyridine), myxothiazol nitric oxide, nefazodone, nonactin, parimifasor (LYC-30937), piericidin A, pioglitazone, pyrvinium, ranolazine, rosiglitazone, rotenone, RTB70, TRC1, OXPHOS-IN-1, SMV-32, stigmatellin, TRAP1-IN-2, TRAP1-IN-1, SCAL-255, SCAL-266, siccanin, tetrathiomolybdate, tiabendazole, and TTFA (thenoyltrifluoroacetone).

### Claim 23 (depends on 20)

The pharmaceutical composition of claim 20, wherein the ROCK1 inhibitor is belumosudil (KD025) and the OXPHOS inhibitor is IACS-010759 (IACS-10759), metformin, phenformin, or IM156.

### Claim 24 (depends on 20)

The pharmaceutical composition of claim 20, wherein said pharmaceutical composition is formulated for oral administration, buccal administration, injection, microneedle administration, vaginal administration, inhalation, intraosseous administration, trans nasal application, topical administration, transdermal application, or rectal administration.

### Claim 25 (depends on 20)

The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is serum-free, endotoxin-free, or sterile.
